Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma
Open Access
- 30 March 2023
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-13
Abstract
Lung adenocarcinoma (LUAD) is one of the most prevalent pathological kinds of lung cancer, which is a common form of cancer that has a high death rate. Over the past several years, growing studies have indicated that GPD1L was involved in the advancement of a number of different cancers. However, its clinical significance in LUAD has not been investigated. In this study, following an examination of the TGCA datasets, we found that GPD1L displayed a dysregulated state in a wide variety of cancers; this led us to believe that GPD1L is an essential regulator in the progression of malignancies. In addition, we found that the expression of GPD1L was much lower in LUAD tissues when compared with nontumor specimens. According to the findings of ROC tests, GPD1L was able to effectively identify LUAD specimens from nontumor samples with an AUC value of 0.828 (95% confidence interval: 0.793 to 0.863). On the basis of the clinical study, a low expression of GPD1L was clearly related with both the N stage and the clinical stage. Moreover, based on the findings of a Kaplan-Meier survival study, elevated GPD1L expression was a strong indicator of considerably improved overall survival (OS) and disease-specific survival (DSS). GPD1L expression and clinical stages were found to be independent prognostic indicators for overall survival and disease-free survival in LUAD patients, according to multivariate analyses. Based on multivariate analysis, the C-indexes and calibration plots of the nomogram demonstrated an effective prediction performance for LUAD patients. Besides, the expression of GPD1L was positively related to mast cells, eosinophils, Tcm, TFH, iDC, DC, and macrophages, while negatively associated with Th2 cells, NK CD56dim cells, Tgd, Treg, and neutrophils. Finally, qRT-PCR was able to demonstrate that GPD1L had a significant amount of expression in LUAD. Additionally, according to the results of functional tests, overexpression of GPD1L had a significant inhibiting effect on the proliferation of LUAD cells. In general, the results of our study suggested that GPD1L had the potential to serve as a diagnostic and prognostic marker for LUAD.Keywords
Funding Information
- Shanghai Sixth People’s Hospital (DY2018005)
This publication has 39 references indexed in Scilit:
- Lung Cancer ScreeningThoracic Surgery Clinics, 2015
- DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysisBioinformatics, 2014
- Lung Cancer Screening Beyond Low-Dose Computed Tomography: The Role of Novel BiomarkersLung, 2014
- The prognostic value of glycerol‐3‐phosphate dehydrogenase 1‐like expression in head and neck squamous cell carcinomaHistopathology, 2013
- Can lung cancer stem cells be targeted for therapies?Cancer Treatment Reviews, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Strength and weakness of the new TNM classification for lung cancerEuropean Respiratory Journal, 2010
- GPD1L links redox state to cardiac excitability by PKC-dependent phosphorylation of the sodium channel SCN5AAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Lung Cancer Screening with CTClinics in Chest Medicine, 2008
- Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequencesProceedings of the National Academy of Sciences, 2002